Conditions

How does diabetes affect the risk of developing late-life mild cognitive impairment or dementia?  

The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes. 

Could older recommendations of maintaining a blood pressure of 140/90 mmHg be misleading in younger adults with type 1 diabetes for cardiovascular risk reduction? 

The results of EMPA-REG OUTCOME Trial assess the role of empagliflozin in patients with type 2 diabetes and atherosclerotic cardiovascular disease.

The lack of studies for children and adolescents with type 2 diabetes has led to an absence of approval of new drugs for this patient population. This study reports findings of Liraglutide for youth.

Myocardial flow reserve plays a significant role as a predictor of cardiac death in patients with diabetes.

New research findings on oral semaglutide vs subcutaneous liraglutide.

The role of 25-hydroxyvitamin D in the progression of type 2 diabetes continues to be explored after a recent study observes diabetes incidence in high risk patients receiving vitamin supplementation.

Thirty years of follow-up data show significant reductions in morbidities and mortality in patients with prediabetes who initiate lifestyle modifications.

Data announced at the 79th annual Scientific Sessions of the ADA shows restoration of beta cell function is possible.